Verve Therapeutics

Verve posts clean PCSK9 editor profile, teeing up Lilly decision

One year after axing an asset, the biotech has shown its Lilly-partnered successor can achieve similar LDL-C reductions without raising any red flags.

Nick Paul Taylor Apr 14, 2025 7:00am

Vertex axes Verve gene editing pact amid shift in R&D priorities

Feb 27, 2025 9:05am

Graphic of someone in a boat navigating the rise and fall of different data riding data plots like a wave

Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor

Apr 2, 2024 7:00am

a 49ers fan lifts his fists in celebration during Sundays NFC Championship

Biotech insiders savor 49ers' latest victory in Super Bowl run

Jan 30, 2024 7:00am

Verve shows base editing works in humans—and sees stock sink

Nov 13, 2023 8:43am

Beam offloads Verve rights to Lilly for up to $600M

Oct 31, 2023 6:00am